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Abstract
Background: To study the effect of Lanconone® (1000 mg) on acute pain on exertion as compared to the standard
of care, Ibuprofen (400 mg).
Method: The study recruited 72 subjects diagnosed with mild to moderate knee joint pain on exertion. Subjects
with Pain Visual Analogue Scale of more than 40 mm were included. Uphill walking was provided as the stressor
using Naughton’s protocol on a treadmill. The subjects walked for 10 minutes continuously followed by a rest
period and baseline pain score for index knee joint was recorded. Subjects were administered a single dose of
Lanconone® (1000 mg)/Ibuprofen (400 mg). Thereafter the same stressor was provided at 0.5, 1, 2, 3, 4, and 6 hours,
subsequently, pain scores were recorded on a visual analogue scale. Double stopwatch method was used to
evaluate the onset of pain relief and time taken to meaningful pain relief.
Result: Both Lanconone® and Ibuprofen showed the first perceived pain relief at 65.31 ± 35.57 mins as compared
to 60.82 ± 32.56 mins respectively. The mean time taken to experience meaningful pain relief in Lanconone® group
was 196.59 ± 70.85 mins compared to 167.13 ± 71.41 mins amongst Ibuprofen group. The meaningful pain relief
continued for 6 hours.
Conclusion: The current study successfully demonstrated rapid pain-relieving potential of Lanconone® which was
comparable to Ibuprofen. No adverse event related to the interventions was reported in the study.
Trial registration: Clinical trials.gov NCT02417506. 21 January 2015.
Keywords: Ibuprofen, Joint pain, Rapid pain relief, Visual analogue scale, Analgesic, Health supplement,
Glucosamine, Nonsteroidal anti-inflammatory drug, Arthritis, Trauma
Background
A Center for Disease Control (CDC) survey in 2010–2012
showed the prevalence of joint pain to be 22.7 % for adults
in the USA. The prevalence of musculoskeletal disorders
is 23.9 % for women and 18.6 % for men. Furthermore, re-
cent World Health Organization statistics for the year
2010 reported a 45 % increase in disability due to muscu-
loskeletal disorders during the past decade [1]. The CDC
has also projected that 25 % of the world population
would be affected by musculoskeletal disorders by the year
2030 [2]. These statistics present only a partial picture be-
cause they do not take into account the contribution of
risk factors associated with obesity, sedentary lifestyle,
sports-related injury, and nutritional deficiencies leading
to these disorders.
Pain and debilitation are the central hallmarks of mus-
culoskeletal disorders [3]. Complete recovery from joint
disease poses a significant challenge to patients and
healthcare providers. Pain plays a major role, as illus-
trated by a study conducted amongst basketball players
where almost 19 % of athletes never resumed their game
owing to pain caused by injury, thus experiencing sub-
optimal postoperative recovery [4]. Similar results were
observed in running, football [5], and other sports [6].
Current regimens for joint pain management include
pharmacological, surgical, and alternative therapies. Surgi-
cal intervention is generally considered a last resort, in the
face of the failure of nonsurgical therapies. Pharmaco-
logical therapies include nonsteroidal anti-inflammatory* Correspondence: shalini@enovatebiolife.com
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drugs (NSAIDs), opioids, corticosteroids, and other anal-
gesics, all of which carry varying degrees of safety risks.
NSAIDs even though are most popular, their long-
term use is frequently reported to be associated with
several safety concerns, such as gastrointestinal erosions
with or without bleeding, cardiovascular risks and hyper-
tension [7–9]. Additionally, increased risk of hyperten-
sion as well as blood glucose destabilization was
observed in older patients [10]. These safety issues fuel
patients’ desires as well as the scientific community’s
quest for safer and effective alternative treatments.
Lanconone® (Enovate Biolife, Wilmington DE, USA) is
a proprietary botanical active compound, which has
demonstrated significant reduction in joint pain in mod-
erate to severe symptoms of osteoarthritis (OA). In an
earlier pilot study [11], use of Lanconone® for chronic
pain over the period of 12 weeks was investigated. How-
ever, reports of rapid pain relief from subjects taking
Lanconone® prompted us to confirm these initial find-
ings with a new study. Presently, there are no marketed
herbal products with demonstrated analgesic activity in
the temporal range of NSAIDs. The present double-
blind, comparator-controlled randomized clinical study
was designed specifically to evaluate the efficacy of
Lanconone® in acute pain, intensity, and onset of pain
relief, against ibuprofen as a NSAID comparator.
Methods
Subjects
The trial was conducted at the outpatient clinics of two
orthopedic surgeons having a regular inflow of subjects
with knee pain. Knee joint pain is an appropriate model
to study pain relief, as the structural changes here are
representative of a stable condition to study acute pain.
A total of 72 males and females between 40 and 60 years
of age with mild to moderate degenerative changes of
the knee joint were randomized in the study.
Subject inclusion criteria
1. History of moderate to severe knee pain on minimal
exertion but no pain at rest.
2. A score ≥40 mm on the pain visual analog scale
(VAS) after walking briskly at a pace of 4 ± 0.5 mph
on a treadmill without elevation for 10 minutes
continuously.
3. Grade II and III joint functionality assessed clinically
as per American Rheumatology Association (ARA)
classification [12] and radiologically as per Kellgren
Lawrence (KL) classification [13].
4. Physician and subject global assessment of joint pain
as “poor” or “very poor” after walking briskly at a
pace of 4 ± 0.5 mph on a treadmill without elevation
for 10 minutes.
Subject exclusion criteria
1. Any other form of arthritis except OA.
2. Neurological origin of pain, limb deformity, or any
other systemic illness that might interfere with the
outcome of the study.
3. Subjects taking intra-articular or oral steroids/
hyaluronic acid/parenteral NSAIDS for a
considerable period.
4. Subject with signs of local lower limb(s) injury.
All subjects provided their well-informed written consent
for participation in the study which was recorded audio-
visually. The study was conducted in compliance with
International Conference on Harmonisation - Good Clin-
ical Practice (ICH-GCP) guidelines. Approval for the study
was granted by Independent Ethics Committee (IEC-Aditya
registered with the Office for Human Research Protections
in the US Department of Health and Human Services
under registration number IRB00006475). The trial was
registered at clinical trials.gov under registration number
NCT02417506.
Study design
This study was a prospective noninferiority, randomized,
double-blind, comparator-controlled, parallel group, mul-
ticenter clinical trial designed to assess the effects of
Lanconone® in acute pain. The subjects were randomized
to one of the two treatment groups, with appropriate
blinding maintained for the subjects, the study coordina-
tors, as well as the investigators. Figure 1 shows the flow
of participants in the study.
Recruitment
During the screening, the subjects were assessed for the
history of pain upon exertion but no pain at rest. They
Fig. 1 Participant flow in the study
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were then asked to walk briskly at a pace of 4 ± 0.5 mph
on a treadmill without elevation for 10 minutes, follow-
ing which they marked the level of pain on the VAS (0
being no pain and 100 being unbearable pain).
Subsequently, a clinical examination was done by the in-
vestigator to determine functionality based on ARA classifi-
cation, defined as pain in the knee joint on most days,
crepitus on motion, morning stiffness ≥30 minutes, age
>50 years, and bony enlargement on palpation [14]. Subjects
fulfilling four out of five criteria were included in the study.
A radiographic image of the index knee joint (refers to
the joint of each subject having the higher VAS score)
was also obtained. The X-ray image was graded for KL
scale [15] by a radiologist and confirmed by the ortho-
pedic surgeons. Subjects graded by the investigators in
grade II (defined as small osteophytes, possible narrow-
ing of the joint) and grade III (defined as multiple, mod-
erately sized osteophytes, definite joint space narrowing,
some sclerotic areas, possible deformation of bone ends)
were enrolled in the study.
A global assessment of knee joint pain by the investigator
and subject was taken, expressed as “very good”, “good”,
“fair”, “poor”, and “very poor”. The subjects with “poor”
and “very poor” assessments were included in the study.
Subjects satisfying all of the inclusion criteria were entered
into the study. Once the subjects qualified at the screening
visit, a washout period of 7 days was ensured prior to the
study start for those on analgesics for knee pain.
Study procedure
On the day of randomization, subjects were again asked
to walk briskly at a pace of 4 ± 0.5 mph on a treadmill
without elevation for 10 minutes to assess the worsening
of pain during the washout period. Knee pain was
assessed by the investigator and the subject. An uphill
walking protocol is considered most appropriate to in-
duce knee pain which would be close to real-life situa-
tions and can be applied to pain in day-to-day wear and
tear [16]. A modified Naughton’s protocol [17] of uphill
walking on a treadmill was provided as the stressor. Sub-
jects were initially familiarized with the treadmill usage
protocol. All instructions were provided clearly to the
subjects. After an initial resting time of 10 minutes, sub-
jects were asked to stride the treadmill belt. The tread-
mill speed was set up to 1 mph with 0° incline for the
first 2 minutes followed by an increase of speed to 2
mph which remained constant thereafter. The inclin-
ation increased by 3.5 % every 2 minutes. Subjects
walked on the treadmill for 10 minutes and marked their
baseline pain intensity using the VAS within 5–10 mi-
nutes of ending the walking protocol. The time gap was
provided to avoid muscle fatigue-related high scores.
They then rested until the next VAS time point.
Immediately after the baseline pain was recorded, sub-
jects were administered a single oral dose of two cap-
sules of Lanconone® or ibuprofen.
Pain VAS scores were assessed at 0.5, 1, 2, 3, 4, 5, and
6 hours post dosing. The subject walked for 10 minutes
prior to all assessment time points, followed by rest for
50 minutes. The subjects rated their pain on VAS scale
5–10 minutes following completion of the treadmill ex-
ercise as per specified protocol.
Treatment
Both Lanconone® and ibuprofen were prepared in orange-
colored capsule size 0 and matched in weight and color.
Each 500 mg capsule of Lanconone® (Enovate Biolife) con-
tained Oroxylum indicum, Withania somnifera, Zingiber
officinale, Commiphora mukul, Smilax china, Pluchea lan-
ceolata and Boswellia serrata. The matched capsule of ibu-
profen (HuBei Granules-biocause Pharmaceutical Co. Ltd,
Yangwan Road, Jingmen, Hubei, China) contained 200 mg
of the active ingredient plus excipients. Both Lanconone®
and ibuprofen were prepared under Good Manufacturing
Practices. Ibuprofen was selected as the comparator for the
study because of its high efficacy to reduce musculoskeletal
pain, its common use as an anti-inflammatory drug, and
its better safety profile amongst NSAIDs. The study sub-
jects were administered two capsules of either Lanconone®
or ibuprofen. Being a single dose study, 100 % compliance
with both interventions was assured.
Pain VAS
The pain VAS has been effectively used to measure
acute as well as chronic pain in degenerative joint condi-
tions [18] and has demonstrated sensitivity to changes in
pain assessed hourly following analgesic therapy [19].
On a scale of 100 mm subdivisions, 0 indicated no pain
and 100 the highest pain. Subjects were asked to rate the
severity of their pain at the screening visit as well as at
baseline and at various time points such as 0.5, 1, 2, 3, 4,
5, and 6 hours. The pain intensity difference was calcu-
lated by comparing pain VAS scores at baseline with
each post-treatment time point.
Onset and time to meaningful pain relief
A “double stop-watch method” was used to determine
first perceived pain relief (reduction in VAS pain by
10 mm, as perceived by the subjects compared with the
recently scored baseline) and time to meaningful pain re-
lief (reduction in VAS pain by 40 mm, as perceived by the
subjects compared with the recently scored baseline), thus
defining the precise onset of the drug action. Immediately
after dosing, the subjects were given two stop watches and
instructed that once they started perceiving the pain relief
for the first time, they were to switch off one of the two
stop watches and hand it to the study coordinator.
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Similarly, when they experienced meaningful pain relief
they were to switch off the second stop-watch. The study
coordinator recorded both time points for pain relief [20].
Safety assessment
The subjects reported to the investigator any adverse
events during the study duration, and the adverse event
was recorded by the investigators. The investigator also
sought causality for each reported adverse event.
Quality assurance
The study was conducted in compliance with the ICH-GCP
guidelines laid down in E6 (R1) as per a preapproved
monitoring and auditing plan by a team independent of the
investigational site (Vedic Lifesciences, Redwood, CA, USA).
Statistical analysis
A randomized treatment list was generated for assigning
each subject to one of two treatment groups. All ana-
lyses were performed using SPSS® software version 10.0
(IBM Corporation, 1 New Orchard Road, Armonk, New
York 10504-1722, United States), using a chi-square test
for categorical data and analysis of variance and Stu-
dent’s t tests (independent unpaired two-sample test) for




Age, height, and weight are presented in Table 1. There
were no significant differences between groups for age
(p = 0.14) and weight (p = 0.74). There was a significant
difference (p <0.05) between groups for height (p = 0.05).
The mean difference in height was in the order of 4 cm;
however, this did not have significant impact on body
mass index (p = 0.08) and therefore the study outcome
was not affected by this difference. The subjects re-
cruited were 18 males and 53 females. However, gender
distribution in both groups was matched (p = 0.24).
Joint health
All subjects included in the study had no pain at rest.
Both groups were matched in their radiological and
functionality assessment at baseline.
Pain VAS score difference
At baseline, the mean pain VAS score was 68.75 ± 10.58
for the Lanconone® group and 67.71 ± 12.85 for the ibu-
profen group (p = 0.71). Pain VAS scores for both groups
declined over 6 hours with significant pain relief seen in
both groups (p <0.05), starting at 0.5 hours, as shown in
Fig. 2. There were no significant differences between
groups at any time points, demonstrating equivalence
between Lanconone® and ibuprofen.
Mean pain intensity difference
At 0.5 hours, the mean pain VAS intensity showed a sig-
nificant fall of 4.2 % for the Lanconone® group and fall of
5.5 % for the ibuprofen group compared to baseline. The
same trend was observed from 1 to 5 hours. At 6 hours,
the mean pain VAS score in Lanconone® subjects
showed a significant fall of 75.0 % and that for ibuprofen
subjects was 80.0 %. The pain intensity difference for the
Lanconone® group followed a downward trend similar to
ibuprofen as shown in Table 2.
Study responders
Subjects demonstrating an overall ≥50 % decrease in pain
intensity were termed responders. The majority of study
subjects fell into this category between 2 and 6 hours after
administration of interventional products. At the end of
2 hours, 19.4 % of subjects in the Lanconone® group
showed ≥50 % pain relief as compared with 25.7 % of sub-
jects in the ibuprofen group. The percentage of re-
sponders rose to 69.4 % in the Lanconone® group as
compared with 80.0 % in the ibuprofen group from 3 to
5 hours. At the end of 6 hours, 88.9 % of the Lanconone®
subjects showed ≥50 % pain relief as compared with
91.4 % for the ibuprofen subjects, with no significant dif-
ference between the groups (p >0.05). These results are
shown in Fig. 3.
Table 1 Demographics
Parameter Lanconone® Ibuprofen p valuea
Number of cases 36 35
Age (years)
Mean 49.56 51.60 0.14
Standard deviation 06.26 05.28
Range 40.00–62.00 41.00–59.00
Height (cm)
Mean 153.19 157.27 0.05*
Standard deviation 07.27 09.67
Range 142.00–169.00 144.00–182.00
Weight (kg)
Mean 65.61 64.71 0.741
Standard deviation 11.20 11.66
Range 48.00–93.00 45.00–92.00
Body mass index (kg/m2)
Mean 27.8 26.19 0.079
Standard deviation 4.15 3.93
Range 19.68–39.21 18.26–37.66
aStudent’s t test
*p <0.05 - Statistically significant
p >0.05 - Not significant
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First perceived pain relief
The mean time taken to perceive pain relief of at least
10 mm on the VAS from baseline by the Lanconone®
group was found to be 65.31 ± 35.57 minutes as com-
pared with 60.82 ± 32.56 minutes in the ibuprofen group.
The two groups were not significantly different in this
respect (p >0.05).
Meaningful pain relief
The mean time taken to experience meaningful pain relief
(a VAS scale value reduction of 40 mm) in the Lanconone®
group was 196.59 ± 70.85 minutes compared with 167.13 ±
71.41 minutes amongst the ibuprofen group. The two
groups were not significantly different in this respect
(p >0.05).
Safety results
As shown in Table 3, three subjects in the Lanconone®
group had adverse events as compared with one subject
in the ibuprofen group. All of the adverse events were
deemed to be not related to either of the products by
the investigators.
Discussion
Pain is a common complaint for all individuals in differ-
ent stages of life. Musculoskeletal pain, being the leading
and the most debilitating condition, is a major cause of
concern for physically active people. The present study
was undertaken to compare the kinetics of pain relief
from Lanconone® 1000 mg versus ibuprofen 400 mg in a
painful knee joint. Several studies have proven ibuprofen
to be efficacious in the management of pain in subjects
with joint pathology [21, 22], albeit with serious side-
effect liabilities.
We found no significant difference in the onset and time
to meaningful pain relief for the two products studied.
Larger studies may be needed to confirm these findings;
however, the present study indicates that Lanconone®
1000 mg is as effective as ibuprofen 400 mg in acute mus-
culoskeletal pain. This to our knowledge is the first such
demonstration by a botanical dietary supplement.
Ibuprofen has been extensively studied in relation to
pain in knee OA [23]. It has been established that pain
in the knee joint correlates well with the pathological
condition of the knee joint [24]; hence the pain VAS for
both groups in our study is comparable because all sub-
jects were in the same stage of OA. Meaningful pain re-
lief is a critical endpoint in pain studies. The American
Pain Society has stated that a pain-relieving effect, al-
though statistically significant, is irrelevant if the pain re-












































Fig. 2 Pain reduction with single dose of Lanconone® versus ibuprofen over 6 hours. VAS visual analog scale
Table 2 Pain intensity difference
Duration
(hours)
Pain intensity difference p valuea
Lanconone® Ibuprofen
0.5 –2.92 ± 04.20 –3.71 ± 05.05 0.477
1 –12.08 ± 09.59 –13.28 ± 11.37 0.632
2 –21.25 ± 11.04 –24.42 ± 16.08 0.337
3 –34.72 ± 14.04 –36.71 ± 16.76 0.590
4 –44.17 ± 17.55 –46.00 ± 15.66 0.644
5 –49.58 ± 14.31 –52.14 ± 14.31 0.454
6 –51.53 ± 15.85 –54.14 ± 12.88 0.448
aAnalysis of variance
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on a 100 mm scale of pain VAS is considered to be clin-
ically significant pain relief [25]. An exploratory study
from 2003 stated that clinically meaningful reduction of
acute pain was achieved with a 40–45 % decrease on a
pain numerical rating scale [26] similar to the pain VAS,
where 0 correlated to no pain and 10 to worst possible
pain. This outcome allied well with our study, wherein
meaningful pain relief was reached at the pain VAS
score of 40 mm. The time to reach meaningful pain re-
lief was similar in both groups.
The ingredients of Lanconone® have a vast body of sci-
entific data. B. serrata has been studied in various animal
and human trials with different inflammatory conditions
such as OA and rheumatoid arthritis, and so forth [27].
The in-vitro studies show that it has cyclooxygenase
(COX) and 5-lipooxygenase (LOX) inhibitor activity. Also,
in a human trial with the use of 30 % acetyl-11-keto-b-
boswellic acid (AKBA), a constituent of boswellia resulted
in the reduction of matrix metalloproteinase-3 which is a
marker for central pain sensitization [28]. C. mukul has
been studied in an animal model in comparison with ibu-
profen and phenyl butazone for its anti-inflammatory ef-
fect [29] in OA. Z. officinale is hypothesized to block the
activity of COX enzymes and leukotrine and prostaglandin
synthesis, thus influencing the pain processing mechan-
ism; it has also been studied for its positive effect on
exercise-induced muscle pain [30]. P. lanceolata has been
found not only to be anti-inflammatory but also to have
good analgesic properties. A preclinical study has com-
pared the anti-inflammatory effect of P. lanceolata with
drugs such as ibuprofen and has proven it to be better
[31]. Thus, the rapid pain relief by Lanconone® may be
due to the combined analgesic effect of these ingredients.
This trial was designed to study the effect of the supple-
ment for pain relief in postexertion acute joint pain. How-
ever, Lanconone® may be of benefit in joint pain that
exacerbates on exertion irrespective of pathological or
non-pathological origin of pain. While this was a study in
a nonathletic population, the data warrant further clinical
work into the use of Lanconone® as a safer alternative for
pain relief in athletes and other populations. Larger, pref-
erably postmarketing, studies may be required to com-
pletely rule out potential side effects of Lanconone®.
Therefore, based on traditional and modern data [32] on
the component ingredients available, it is not unreason-
able to propose Lanconone® for long-term use as a potent
and rapid action analgesic for acute joint pain.
The pain-relieving effect of Lanconone® could not be
studied beyond 6 hours because of methodological and
ethical challenges. However, the pain levels in both
groups at the end of 6 hours were in the 10–20 range on
the VAS scale, indicating that the analgesic effect for
1000 mg of Lanconone® would probably persist for a
considerable time beyond 6 hours.
Conclusion
Lanconone®, a proprietary botanical active compound, was
proven to be efficacious for joint health on chronic admin-
istration in an earlier randomized placebo-controlled trial.
The present study demonstrated rapid pain relieving po-
tential of Lanconone® which is comparable with that of
Ibuprofen, one of the most widely used NSAIDs.
Lanconone® can thus be used as a safe standalone
short-term and long-term analgesic, as well as a good
Fig. 3 Distribution of responders across the Lanconone® and ibuprofen groups
Table 3 Safety results
Adverse event Lanconone® Ibuprofen p valuea
(n = 36) (n = 35)
Mild giddiness 2 0
Vertigo 1 0
Breathlessness 0 1
Total number of subjects 3 1 0.303
aChi-square test
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complement to potent chondroprotective agents and anti-
inflammatory supplements, which are presently facing
controversies not only regarding their role in pain
and inflammation [1] but also their role in cartilage
rebuilding [33].
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